SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

The rally toward fresh highs is drawing attention ahead of the expected Q3 report, with traders weighing BRIUMVIs growth against unconfirmed buyout speculation and possible short-covering. Some see the move as a bet on earnings and the companys commercial prospects rather than an acquisition; no deal has been confirmed.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its prespecified 80th death event has triggered final analysis, with topline results expected this quarter. Traders are divided over whether GPS improved survival: bullish holders see the pending readout as a major catalyst, while bears question the efficacy case, and the share-price decline has intensified debate about selling pressure and alleged short activity.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens PAPZIMEOS commercial launch and stronger-than-expected quarterly results, including a move to profitability, are driving bullish discussion about its growth prospects. Traders also debate whether potential INO-3107 competition could challenge PAPZIMEOS and whether heavy short interest is amplifying the stocks moves.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal suspension have fueled Bitcoin selling and concerns about crypto exchange security. Traders disagree over whether the incident signals broader risk or is isolated to Binance, with some viewing the pullback as a buying opportunity and others warning of further downside.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARM is drawing attention amid a steep pullback from its highs, with traders citing semiconductor weakness, profit-taking and concerns that its valuation assumes years of strong AI-driven growth. Bulls point to potential data-center CPU demand and ARMs role in AI infrastructure, while bears question whether growth can justify the premium; the upcoming earnings report is a focus.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A sharp selloff in silver and other precious metals is driving attention, with inflation concerns tied to higher energy prices and expectations of tighter interest rates weighing on the market. Traders are split between calling the decline a continuing routsometimes alleging manipulationand seeing oversold conditions as a possible buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Federal Realty's Q3 FFO Beat Estimates on Rental Growth & Strong Leasing

FRT's Q3 2026 FFO beat estimates as rental income and leasing spreads grew, prompting higher full-year guidance amid strong property performance.

KIM Q3 FFO Beats on Strong Leasing, Revenues Miss, 2026 Outlook Raised

Kimco Realty's Q3 2026 FFO rises 6.8% to 47 cents per share, beating estimates as leasing gains lift occupancy and prompt higher full-year guidance.

Kimco Realty (KIM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Kimco Realty (KIM) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Kimco Realty Q3 FFO Rises; Increases 2026 Outlook

(RTTNews) - Kimco Realty (KIM) reported third quarter FFO of $316.2 million, or $0.47 per diluted share, compared to $300.3 million, or $0.44 per diluted share, a year ago. Net income for the third quarter was $272.5 million, or $0.41 per diluted share, compared to $130.2 million...

Kimco Realty (KIM) Surpasses Q3 FFO Estimates

Kimco Realty (KIM) delivered FFO and revenue surprises of +2.17% and -0.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Kimco Realty Corp. Profit Climbs In Q3

(RTTNews) - Kimco Realty Corp. (KIM) revealed earnings for its third quarter that Increased, from last year...

Kimco Realty Stock Before Q3 Earnings: Smart Buy or Risky Move?

KIM's Q3 results may benefit from strong leasing, rising rents and grocery-anchored demand, with revenues and FFO per share expected to grow year over year.

Modal Raises $750 Million in Series D Round: NYSE Content Update

Modal Raises $750 Million in Series D Round: NYSE Content Update Modal Raises $750 Million in Series D Round: NYSE Content UpdatePR NewswireNEW YORK, Oct. 27, 2026 NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Oct. 27, 2026 /PRNewswire/ -- The New York Stock...

Why Kimco Realty (KIM) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Kimco Realty (KIM) have what it takes? Let's find out.

Is it Wise to Retain Macerich Stock in Your Portfolio Now?

MAC's premium malls, rising occupancy and a $124M signed-not-open pipeline support growth, while tenant bankruptcies and e-commerce competition pose risks.

$KIM Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.41 up 115.79% YoY
• Reported revenue of $546.15M up 1.92% YoY
• Kimco Realty raised its 2026 full-year outlook: net income per diluted share to $1.07$1.09 from $1.00$1.03 and FFO per diluted share to $1.84$1.86 from $1.83$1.84.

Stocktwits

Kimco Realty Corp.

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.41 up 115.79% YoY
• Reported revenue of $546.15M up 1.92% YoY
• Kimco Realty raised its 2026 full-year outlook: net income per diluted share to $1.07$1.09 from $1.00$1.03 and FFO per diluted share to $1.84$1.86 from $1.83$1.84.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $0.41 up 115.79% YoY
• Reported revenue of $546.15M up 1.92% YoY
• Kimco Realty raised its 2026 full-year outlook: net income per diluted share to $1.07$1.09 from $1.00$1.03 and FFO per diluted share to $1.84$1.86 from $1.83$1.84.

Kimco Realty reported higher impairment charges and interest expense year over year, while identifying e-commerce and consumer buying changes and major-tenant rent-payment risks among potential business risks.

Kimco Realty reported record 96.6% portfolio occupancy, 31.5% pro-rata cash rent spreads on comparable new leases and 4.9% same-property NOI growth, and sold The Witmer while repurchasing $150M of common stock.

Kimco Realty Corp. is a real estate investment trust company, which engages in the ownership and operation of open-air and grocery-anchored shopping centers. It also specializes in shopping center acquisitions, development and management. The company was founded by Milton Cooper and Martin S. Kimmel in 1973 and is headquartered in Jericho, NY.

Kimco Realty Corporation

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$24.52
Prev Close	$24.42
Open	$24.55
Dividend Yield	4.98%
50-Day Moving Average	$23.05
Beta	0.58
Avg. Volume	5.61M
PE Ratio	28.63

52-Week High	$26.65
52-Week Low	$19.76
Market Capitalization	$16.38B
EPS (Annual)	$0.8163
Price to Book	1.59
Revenue Per Employee	$3.03M

Feed

News

Sentiment

Earnings

Fundamentals

Info

KIM Fundamentals